Next-generation sequencing for adventitious virus detection in biologics: EDQM collaborates on article published in Biologicals (from Catapult’s regulatory round-up – November 2023)
The EDQM has co-authored a report with academics and interested parties, entitled “Report of the third conference on next-generation sequencing for adventitious virus detection in biologics for humans and animals”.
It reports on an International Alliance for Biological Standardization (IABS) conference held in September 2022 that emphasized the significant progress made in next-generation sequencing (NGS, also called high-throughput sequencing, or HTS) overcoming limitations of current testing methods for adventitious virus detection in biologics.
The conference, organised by the EDQM and FDA gathered international representatives from regulatory and public health authorities and other government agencies, industry, contract research organizations, as well as academia to present the current status of NGS applications and the progress on NGS standardization and validation for detection of viral adventitious agents in biologics, including human and animal vaccines, gene therapies, and biotherapeutics.
Published on the 5th of december 2023. Read Catapult’s entire regulatory round-up here.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (21 mai 2024). Next-generation sequencing for adventitious virus detection in biologics: EDQM collaborates on article published in Biologicals (from Catapult’s regulatory round-up – November 2023). ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/11p03





